Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry

European Journal of Medicinal Chemistry
2019.0

Abstract

The 4-aminoquinazoline core is an interesting pharmacophore and its applications in medicinal chemistry are wide spread. The core has been used for making many kinase inhibitors in past few years. Many researcher demonstrated 4-aminoquinazoline derivatives as specific kinase inhibitors, including tyrosine kinase and serine/theronine kinases. A number of anticancer drugs with 4-aminoquinazoline core are in the market, e.g. gefitinib, erlotinib, afatinib, lapatinib, decomitinib etc. 4-aminoquinazoline derivatives are applied for target specific treatment of lung, breast, colon, prostate cancers. In this review, we discussed the current development of 4-aminoquinazoline derivatives as kinase inhibitors and their uses as anticancer agents in recent years.

Knowledge Graph

Similar Paper

Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry
European Journal of Medicinal Chemistry 2019.0
Discovery of 4-aminoquinazoline—urea derivatives as Aurora kinase inhibitors with antiproliferative activity
Bioorganic & Medicinal Chemistry 2014.0
Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents
Bioorganic & Medicinal Chemistry 2016.0
Development of 2, 4-diaminoquinazoline derivatives as potent PAK4 inhibitors by the core refinement strategy
European Journal of Medicinal Chemistry 2017.0
Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase
Bioorganic & Medicinal Chemistry Letters 2012.0
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton
Bioorganic & Medicinal Chemistry 2019.0
Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors
Bioorganic & Medicinal Chemistry Letters 2013.0
Novel 4-arylaminoquinazoline derivatives with ( E )-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells
European Journal of Medicinal Chemistry 2017.0
Therapeutic progression of quinazolines as targeted chemotherapeutic agents
European Journal of Medicinal Chemistry 2021.0
Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro
European Journal of Medicinal Chemistry 2017.0